<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PCOMPBIOL-D-11-01035</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1002307</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Computational biology</subject>
          </subj-group>
          <subj-group>
            <subject>Theoretical biology</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Gastroenterology and hepatology</subject>
          </subj-group>
          <subj-group>
            <subject>Infectious diseases</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
          <subject>Computational Biology</subject>
          <subject>Gastroenterology and Hepatology</subject>
        </subj-group>
      </article-categories><title-group><article-title>Mathematical Model of Viral Kinetics In Vitro Estimates the Number of E2-CD81 Complexes Necessary for Hepatitis C Virus Entry</article-title><alt-title alt-title-type="running-head">Number of E2-CD81 Complexes Required for HCV Entry</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Padmanabhan</surname>
            <given-names>Pranesh</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Dixit</surname>
            <given-names>Narendra M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Chemical Engineering, Indian Institute of Science, Bangalore, India</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Bioinformatics Centre, Indian Institute of Science, Bangalore, India</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Regoes</surname>
            <given-names>Roland Robert</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">ETH, Switzerland</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">narendra@chemeng.iisc.ernet.in</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: PP NMD. Performed the experiments: PP. Analyzed the data: PP NMD. Contributed reagents/materials/analysis tools: PP NMD. Wrote the paper: PP NMD.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <month>12</month>
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>8</day>
        <month>12</month>
        <year>2011</year>
      </pub-date><volume>7</volume><issue>12</issue><elocation-id>e1002307</elocation-id><history>
        <date date-type="received">
          <day>16</day>
          <month>7</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>10</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Padmanabhan, Dixit</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
        <p>Interaction between the hepatitis C virus (HCV) envelope protein E2 and the host receptor CD81 is essential for HCV entry into target cells. The number of E2-CD81 complexes necessary for HCV entry has remained difficult to estimate experimentally. Using the recently developed cell culture systems that allow persistent HCV infection in vitro, the dependence of HCV entry and kinetics on CD81 expression has been measured. We reasoned that analysis of the latter experiments using a mathematical model of viral kinetics may yield estimates of the number of E2-CD81 complexes necessary for HCV entry. Here, we constructed a mathematical model of HCV viral kinetics in vitro, in which we accounted explicitly for the dependence of HCV entry on CD81 expression. Model predictions of viral kinetics are in quantitative agreement with experimental observations. Specifically, our model predicts triphasic viral kinetics in vitro, where the first phase is characterized by cell proliferation, the second by the infection of susceptible cells and the third by the growth of cells refractory to infection. By fitting model predictions to the above data, we were able to estimate the threshold number of E2-CD81 complexes necessary for HCV entry into human hepatoma-derived cells. We found that depending on the E2-CD81 binding affinity, between 1 and 13 E2-CD81 complexes are necessary for HCV entry. With this estimate, our model captured data from independent experiments that employed different HCV clones and cells with distinct CD81 expression levels, indicating that the estimate is robust. Our study thus quantifies the molecular requirements of HCV entry and suggests guidelines for intervention strategies that target the E2-CD81 interaction. Further, our model presents a framework for quantitative analyses of cell culture studies now extensively employed to investigate HCV infection.</p>
      </abstract><abstract abstract-type="summary">
        <title>Author Summary</title>
        <p>The interaction between the hepatitis C virus (HCV) envelope protein E2 and the host cell surface receptor CD81 is critical for HCV entry into hepatocytes and presents a promising drug and vaccine target. Yet, the number of E2-CD81 complexes that must be formed between a virus and a target cell to enable viral entry remains unknown. Direct observation of the E2-CD81 complexes preceding viral entry has not been possible. We constructed a mathematical model of HCV viral kinetics in vitro and using it to analyze data from recent cell culture studies obtained estimates of the threshold number of E2-CD81 complexes necessary for HCV entry. We found that depending on the E2-CD81 binding affinity, between 1 and 13 complexes are necessary for HCV entry into human hepatoma-derived cells. Our study thus presents new, quantitative insights into the molecular requirements of HCV entry, which may serve as a guideline for intervention strategies targeting the E2-CD81 interaction. Further, our study shows that HCV viral kinetics in vitro can be described using a mathematical model, thus facilitating quantitative analyses of the wealth of data now emanating from cell culture studies of HCV infection.</p>
      </abstract><funding-group><funding-statement>This work was supported by the Department of Biotechnology Centre of Excellence for Research on Hepatitis C Virus, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="11"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>HCV entry into target cells is a complex process involving the interactions of the viral envelope proteins E1 and E2 and several cell surface receptors, namely, scavenger receptor class B type I (SR-BI) <xref ref-type="bibr" rid="pcbi.1002307-Scarselli1">[1]</xref>, the tetraspanin CD81 <xref ref-type="bibr" rid="pcbi.1002307-Pileri1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Cormier1">[3]</xref>, and the tight junction proteins claudin-1 (CLDN1) <xref ref-type="bibr" rid="pcbi.1002307-Evans1">[4]</xref> and occludin <xref ref-type="bibr" rid="pcbi.1002307-Ploss1">[5]</xref>. Several recent studies suggest a central role for CD81 in HCV entry: E2 has been shown to interact directly with SR-BI and CD81 following viral attachment to a target cell <xref ref-type="bibr" rid="pcbi.1002307-Scarselli1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Pileri1">[2]</xref>. Patient derived neutralizing antibodies appear to target the CD81 binding domains on E2 <xref ref-type="bibr" rid="pcbi.1002307-Law1">[6]</xref>. Indeed, anti-CD81 antibodies were able to block infection in vitro <xref ref-type="bibr" rid="pcbi.1002307-Cormier1">[3]</xref> and in a mouse model <xref ref-type="bibr" rid="pcbi.1002307-Dorner1">[7]</xref>. Graft reinfection following liver transplantation was observed recently to select for HCV strains capable of more efficient entry, achieved partly through mutations in the CD81 binding domains on E2 <xref ref-type="bibr" rid="pcbi.1002307-FafiKremer1">[8]</xref>. Expression of human CD81 and occludin was essential for infection of genetically humanized mice <xref ref-type="bibr" rid="pcbi.1002307-Dorner1">[7]</xref>. Besides, CLDN1 appears to mediate HCV entry through its association with CD81 <xref ref-type="bibr" rid="pcbi.1002307-Krieger1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Harris1">[10]</xref>. Consequently, the E2-CD81 interaction presents a potent target for intervention; drugs that block the E2-CD81 interaction are currently under development <xref ref-type="bibr" rid="pcbi.1002307-Lemon1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Zeisel1">[12]</xref>.</p>
      <p>How many E2-CD81 complexes must be formed between a virion and a target cell to enable HCV entry? Knowledge of this threshold would determine the number of E2-CD81 complexes that a drug or a vaccine must prevent from forming in order to block viral entry, thus presenting a quantitative guideline for intervention strategies targeting the E2-CD81 interaction. This threshold is currently unknown. Direct observation of the number of E2-CD81 complexes formed before HCV entry has not been possible. Recent cell culture studies have determined the dependence of viral entry and kinetics in vitro on the CD81 expression level on target cells <xref ref-type="bibr" rid="pcbi.1002307-Harris1">[10]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref>–<xref ref-type="bibr" rid="pcbi.1002307-Zhang1">[18]</xref>. In particular, cells expressing higher levels of CD81 were found to be more susceptible to infection <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref>. Further, the frequency of cells with low CD81 expression typically increased with time following the exposure of cells to HCV <xref ref-type="bibr" rid="pcbi.1002307-Tscherne1">[14]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref>. We reasoned that analysis of these observations using a mathematical model of viral kinetics, akin to studies of HIV entry (for example, see <xref ref-type="bibr" rid="pcbi.1002307-Magnus1">[19]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Mulampaka1">[20]</xref>), may allow estimation of the threshold number of E2-CD81 complexes necessary for HCV entry. While models of HCV viral kinetics in vivo have been employed successfully to analyse patient data and elucidate guidelines for treatment <xref ref-type="bibr" rid="pcbi.1002307-Neumann1">[21]</xref>–<xref ref-type="bibr" rid="pcbi.1002307-Hsu1">[31]</xref>, models of HCV viral kinetics in vitro have just begun to be formulated.</p>
      <p>Here, we constructed a mathematical model of HCV viral kinetics in vitro that mimics cell culture studies of the dependence of viral entry and kinetics on CD81 expression. Model predictions captured data from several independent experiments quantitatively and yielded estimates of the threshold number of E2-CD81 complexes necessary for HCV entry.</p>
    </sec>
    <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
        <title>Model formulation</title>
        <p>We considered in vitro experiments where a population of target cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e001" xlink:type="simple"/></inline-formula>, with a known distribution of the CD81 expression level across cells is exposed to a population of HCVcc (cell culture adapted) virions, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e002" xlink:type="simple"/></inline-formula>, and the progression of infection followed <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref>–<xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref>. We modelled the ensuing viral kinetics as follows (<xref ref-type="fig" rid="pcbi-1002307-g001">Fig. 1</xref>). We first considered a single virus-cell pair with the virus attached to the cell by interactions that precede E2-CD81 binding <xref ref-type="bibr" rid="pcbi.1002307-Zeisel1">[12]</xref>. E2 and CD81 then interact to form E2-CD81 complexes. We computed the mean number of these complexes formed at equilibrium, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e003" xlink:type="simple"/></inline-formula>, as a function of the CD81 expression level, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e004" xlink:type="simple"/></inline-formula>, on the cell. Assuming that the number of complexes formed, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e005" xlink:type="simple"/></inline-formula>, followed a Poisson distribution with mean <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e006" xlink:type="simple"/></inline-formula>, we computed the probability, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e007" xlink:type="simple"/></inline-formula>, that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e008" xlink:type="simple"/></inline-formula> was larger than a threshold number <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e009" xlink:type="simple"/></inline-formula>. We assumed that viral entry (and subsequently infection) occurred if <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e010" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g001">Fig. 1A</xref>). Thus, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e011" xlink:type="simple"/></inline-formula> yielded the relative susceptibility to infection of a cell with CD81 expression level <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e012" xlink:type="simple"/></inline-formula>.</p>
        <fig id="pcbi-1002307-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pcbi.1002307.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Schematic of the model.</title>
            <p>(A) HCV enters a target cell if the number of E2-CD81 complexes formed across the virus-cell pair, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e013" xlink:type="simple"/></inline-formula>, exceeds the threshold, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e014" xlink:type="simple"/></inline-formula> (top), but not otherwise (bottom). (B) Viral kinetics following the exposure of cells with a distribution of the CD81 expression level (left) to virions in vitro is determined by the time-evolution of subpopulations 1 through <italic>K</italic> of cells with distinct CD81 expression levels and hence different susceptibilities to HCV entry (right).</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.g001" xlink:type="simple"/>
        </fig>
        <p>We next considered the population of cells exposed to virions (<xref ref-type="fig" rid="pcbi-1002307-g001">Fig. 1B</xref>). We divided the cells into different subpopulations <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e015" xlink:type="simple"/></inline-formula> with distinct CD81 expression levels <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e016" xlink:type="simple"/></inline-formula> and hence different susceptibilities <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e017" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e018" xlink:type="simple"/></inline-formula>. Cells in each subpopulation were assumed to proliferate, die, or be infected at a rate proportional to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e019" xlink:type="simple"/></inline-formula>. The resulting infected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e020" xlink:type="simple"/></inline-formula>, were lost at enhanced rates compared to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e021" xlink:type="simple"/></inline-formula> due to virus-induced cytopathicity in vitro <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Walters1">[32]</xref>. Free virions were produced by infected cells and were cleared. With this description, we constructed dynamical equations to predict the time-evolution of each of the uninfected and infected cell subpopulations and the population of free virions and compared our predictions with experiments (<xref ref-type="sec" rid="s4">Methods</xref>).</p>
      </sec>
      <sec id="s2b">
        <title>Model predictions</title>
        <sec id="s2b1">
          <title>Triphasic viral kinetics in vitro</title>
          <p>When cells with a log-normal distribution of the CD81 expression level (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2A</xref> inset) were exposed to virions in vitro, we found that infection proceeded in three phases (<xref ref-type="fig" rid="pcbi-1002307-g002">Figs. 2A and B</xref>). In the first phase, the population of uninfected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e022" xlink:type="simple"/></inline-formula>, rose, as their net proliferation rate dominated their loss rate by infection. At the same time, exposure of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e023" xlink:type="simple"/></inline-formula> to virions resulted in the growth of infected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e024" xlink:type="simple"/></inline-formula>. Initially, because <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e025" xlink:type="simple"/></inline-formula> was small, viral production was dominated by clearance, resulting in a decline of the viral load, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e026" xlink:type="simple"/></inline-formula>. As <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e027" xlink:type="simple"/></inline-formula> increased, viral production compensated for clearance and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e028" xlink:type="simple"/></inline-formula> began to rise. Subsequently, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e029" xlink:type="simple"/></inline-formula> evolved proportionally to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e030" xlink:type="simple"/></inline-formula>, indicating the establishment of a pseudo-steady state between viral production and clearance, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e031" xlink:type="simple"/></inline-formula>.</p>
          <fig id="pcbi-1002307-g002" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pcbi.1002307.g002</object-id>
            <label>Figure 2</label>
            <caption>
              <title>Model predictions of HCV viral kinetics in vitro.</title>
              <p>The time evolution of (A) uninfected cells, <italic>T</italic>, (B) infected cells, <italic>I</italic>, and viral load, <italic>V</italic>, (C) uninfected cell sub-populations, <italic>T<sub>i</sub></italic>, and (lower inset) infected cell sub-populations, <italic>I<sub>i</sub></italic>, corresponding to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e032" xlink:type="simple"/></inline-formula> (dot-dashed line), 0.5 (dotted line) and 1 (solid line), and (D) the total fraction of cells infected, <italic>ψ</italic>. The initial CD81 distribution, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e033" xlink:type="simple"/></inline-formula>, as a function of the CD81 expression level, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e034" xlink:type="simple"/></inline-formula>, is presented in the inset in (A). The three phases of infection are also marked in (A). Inset in (B) shows <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e035" xlink:type="simple"/></inline-formula> as a function of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e036" xlink:type="simple"/></inline-formula>. Upper inset in (C) shows the time evolution of the mean CD81 surface density. Inset in (D) shows the fractions of cells infected in sub-populations with distinct CD81 expression levels, <italic>ξ<sub>i</sub></italic>, at different post-infection times. In (A), (B), (D) and the upper inset in (C), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e037" xlink:type="simple"/></inline-formula> (red line), 4 (blue line), and 6 (green line). In (C) and the inset in (D), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e038" xlink:type="simple"/></inline-formula>. Other parameter values employed are <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e039" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e040" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e041" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e042" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e043" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e044" xlink:type="simple"/></inline-formula>;<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e045" xlink:type="simple"/></inline-formula>. Initial conditions are <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e046" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e047" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e048" xlink:type="simple"/></inline-formula>.</p>
            </caption>
            <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.g002" xlink:type="simple"/>
          </fig>
          <p>In the second phase, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e049" xlink:type="simple"/></inline-formula> was sufficiently large that the loss of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e050" xlink:type="simple"/></inline-formula> by infection outweighed cell proliferation, resulting in a decline of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e051" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2A</xref>). This decline was consequently associated with a steep rise in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e052" xlink:type="simple"/></inline-formula> and correspondingly <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e053" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2B</xref>). In the third phase, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e054" xlink:type="simple"/></inline-formula> rose again while <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e055" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e056" xlink:type="simple"/></inline-formula> remained nearly constant. This third phase resulted from diverse kinetic profiles of subpopulations of cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e057" xlink:type="simple"/></inline-formula>, expressing different levels of CD81, which we describe below.</p>
        </sec>
        <sec id="s2b2">
          <title>Dependence of viral kinetics on CD81 expression</title>
          <p>The relative susceptibility of cells to infection, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e058" xlink:type="simple"/></inline-formula>, depends on the CD81 expression level, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e059" xlink:type="simple"/></inline-formula>, and the parameters <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e060" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e061" xlink:type="simple"/></inline-formula> (equilibrium dissociation constant or the inverse of affinity) (Eqs. (4) and (5)). For fixed <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e062" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e063" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e064" xlink:type="simple"/></inline-formula> increased with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e065" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2B</xref> inset). Above a certain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e066" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e067" xlink:type="simple"/></inline-formula>), CD81 did not limit entry and cells were nearly completely susceptible to infection (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e068" xlink:type="simple"/></inline-formula>). At the same time, below a certain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e069" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e070" xlink:type="simple"/></inline-formula>), cells were refractory to infection (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e071" xlink:type="simple"/></inline-formula>). This variation in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e072" xlink:type="simple"/></inline-formula> led to diverse kinetic profiles.</p>
          <p>In the first phase of viral kinetics, all subpopulations <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e073" xlink:type="simple"/></inline-formula> grew because infection rates were low and cell proliferation dominated (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2C</xref>). In the second phase, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e074" xlink:type="simple"/></inline-formula> declined for subpopulations with sufficiently large <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e075" xlink:type="simple"/></inline-formula> that infection dominated proliferation (e.g., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e076" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e077" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2C</xref>). The corresponding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e078" xlink:type="simple"/></inline-formula> accordingly rose (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2C</xref> lower inset). Eventually, nearly all cells in these subpopulations were infected and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e079" xlink:type="simple"/></inline-formula> vanished leaving behind a pool of infected cells. This pool remained constant over the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e080" xlink:type="simple"/></inline-formula> d period considered here because the lifespan of infected cells assumed was much larger, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e081" xlink:type="simple"/></inline-formula> d. Correspondingly, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e082" xlink:type="simple"/></inline-formula> also remained nearly constant (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2B</xref>). In contrast, subpopulations with low <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e083" xlink:type="simple"/></inline-formula> were not easily infected and continued to grow throughout (<italic>e.g.</italic>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e084" xlink:type="simple"/></inline-formula> in <xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2C</xref>). The growth of the latter cells resulted in the rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e085" xlink:type="simple"/></inline-formula> in the third phase of infection (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2A</xref>).</p>
          <p>Indeed, at any time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e086" xlink:type="simple"/></inline-formula>, the fraction of cells infected within any subpopulation, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e087" xlink:type="simple"/></inline-formula>, increased with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e088" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2D</xref> inset). For large <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e089" xlink:type="simple"/></inline-formula>, CD81 did not limit infection (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e090" xlink:type="simple"/></inline-formula>) so that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e091" xlink:type="simple"/></inline-formula> evolved independently of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e092" xlink:type="simple"/></inline-formula>. Eventually, all cells in the latter subpopulations were infected and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e093" xlink:type="simple"/></inline-formula> approached <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e094" xlink:type="simple"/></inline-formula>. Below a certain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e095" xlink:type="simple"/></inline-formula>, however, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e096" xlink:type="simple"/></inline-formula> was so low that hardly any cells were infected and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e097" xlink:type="simple"/></inline-formula> remained vanishingly small. These latter subpopulations, refractory to infection, ultimately dominated the target cell population. That a majority of the cells in the third phase was refractory to infection was also evident from the time-evolution of the total fraction of cells infected, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e098" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2D</xref>). <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e099" xlink:type="simple"/></inline-formula> increased initially as cells with high <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e100" xlink:type="simple"/></inline-formula> were infected. After a majority of the latter cells was infected, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e101" xlink:type="simple"/></inline-formula> remained constant whereas the population of cells refractory to infection increased, resulting in a decrease of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e102" xlink:type="simple"/></inline-formula>. Accordingly, the mean CD81 expression also decreased (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2C</xref> upper inset). Even with low susceptibility, however, stochastic events may result in the formation of the threshold number of complexes and allow viral entry. As <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e103" xlink:type="simple"/></inline-formula> increased, the frequency of such stochastic events grew and resulted in the growth of the corresponding <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e104" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2C</xref> lower inset), which in turn resulted in the subtle rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e105" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e106" xlink:type="simple"/></inline-formula> towards the end of the third phase (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2B</xref>).</p>
        </sec>
        <sec id="s2b3">
          <title>Influence of model parameters</title>
          <p>As <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e107" xlink:type="simple"/></inline-formula> increased, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e108" xlink:type="simple"/></inline-formula> decreased (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2B</xref> inset), increasing the fraction of cells refractory to infection and hence lowering <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e109" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2D</xref>). Accordingly, the rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e110" xlink:type="simple"/></inline-formula> in the third phase was enhanced upon increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e111" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2A</xref>). As <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e112" xlink:type="simple"/></inline-formula> increased, the frequency of stochastic events leading to entry into cells with low <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e113" xlink:type="simple"/></inline-formula> increased and resulted in a slightly greater increase of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e114" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e115" xlink:type="simple"/></inline-formula> towards the end of the third phase (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2B</xref>). Variations in other model parameters introduced similar quantitative variations but did not alter the triphasic kinetics qualitatively (<xref ref-type="supplementary-material" rid="pcbi.1002307.s001">Fig. S1</xref>). Below, we present comparisons of our model with experiments.</p>
        </sec>
      </sec>
      <sec id="s2c">
        <title>Comparison with experiments</title>
        <sec id="s2c1">
          <title>HCV viral kinetics in vitro</title>
          <p>We considered first the experiments of Zhong et al. <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref>, who measured the kinetics of the growth of Huh-7.5.1 cells with and without exposure to JFH-1 virions. We solved model equations using the initial CD81 distribution corresponding to Huh-7.5 cells <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref> (<xref ref-type="sec" rid="s4">Methods</xref>) (<xref ref-type="supplementary-material" rid="pcbi.1002307.s002">Fig. S2</xref>). We fit model predictions of the time-evolution of the population of viable cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e116" xlink:type="simple"/></inline-formula>, and of the ratio of the populations of dead and viable cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e117" xlink:type="simple"/></inline-formula>, simultaneously to the corresponding experimental data in the absence of infection (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e118" xlink:type="simple"/></inline-formula>). Our model provided good fits to the data and yielded estimates of the proliferation and death rates, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e119" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e120" xlink:type="simple"/></inline-formula>, of uninfected Huh-7.5.1 cells (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3A</xref>). It follows from our model that in the absence of infection (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e121" xlink:type="simple"/></inline-formula>), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e122" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e123" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e124" xlink:type="simple"/></inline-formula> is the population of cells at the start of infection. In agreement, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e125" xlink:type="simple"/></inline-formula> rose linearly on a semi-log plot and the ratio <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e126" xlink:type="simple"/></inline-formula> remained nearly constant (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3A</xref>).</p>
          <fig id="pcbi-1002307-g003" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pcbi.1002307.g003</object-id>
            <label>Figure 3</label>
            <caption>
              <title>Comparisons with experiments.</title>
              <p>(A) Fits of model predictions (lines) to data <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref> (symbols) of the time-evolution of the population of viable cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e127" xlink:type="simple"/></inline-formula>, and the ratio of the populations of dead and viable cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e128" xlink:type="simple"/></inline-formula>, in the absence of infection using <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e129" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e130" xlink:type="simple"/></inline-formula> as adjustable parameters. Initial conditions: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e131" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e132" xlink:type="simple"/></inline-formula>. (B) Fits of model predictions (lines) to data (symbols) <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref> of the time-evolution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e133" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e134" xlink:type="simple"/></inline-formula>, and the viral titre, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e135" xlink:type="simple"/></inline-formula>, using <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e136" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e137" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e138" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e139" xlink:type="simple"/></inline-formula> as adjustable parameters and with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e140" xlink:type="simple"/></inline-formula>. Initial conditions: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e141" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e142" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e143" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e144" xlink:type="simple"/></inline-formula>. (C) Fits of model predictions (lines) of fractions of cells infected in sub-populations with distinct CD81 expression levels, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e145" xlink:type="simple"/></inline-formula>, at day 3 post-infection to data <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref> (symbols) using <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e146" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e147" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e148" xlink:type="simple"/></inline-formula> as adjustable parameters and with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e149" xlink:type="simple"/></inline-formula>. Initial conditions: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e150" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e151" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e152" xlink:type="simple"/></inline-formula> (MOI∼1; circles) or <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e153" xlink:type="simple"/></inline-formula> (MOI∼5; diamonds). Fits with other values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e154" xlink:type="simple"/></inline-formula> are presented in <xref ref-type="supplementary-material" rid="pcbi.1002307.s004">Fig. S4</xref>. The best-fit parameters are in <xref ref-type="supplementary-material" rid="pcbi.1002307.s010">Tables S1</xref> and <xref ref-type="supplementary-material" rid="pcbi.1002307.s011">S2</xref>. (D) Model prediction (line) of the time-evolution of the fraction of cells infected, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e155" xlink:type="simple"/></inline-formula>, compared with data <xref ref-type="bibr" rid="pcbi.1002307-Tscherne1">[14]</xref> (symbols). Initial conditions used: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e156" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e157" xlink:type="simple"/></inline-formula>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e158" xlink:type="simple"/></inline-formula>. Other parameters are the same as in (A). Comparisons with other values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e159" xlink:type="simple"/></inline-formula> are presented in <xref ref-type="supplementary-material" rid="pcbi.1002307.s004">Fig. S4</xref>.</p>
            </caption>
            <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.g003" xlink:type="simple"/>
          </fig>
          <p>Using <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e160" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e161" xlink:type="simple"/></inline-formula> estimated thus and recognizing that viral production and clearance rapidly attain pseudo-steady state (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e162" xlink:type="simple"/></inline-formula>, which implies that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e163" xlink:type="simple"/></inline-formula>), we next fit our predictions of the time-evolution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e164" xlink:type="simple"/></inline-formula>, the ratio <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e165" xlink:type="simple"/></inline-formula>, and the viral load, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e166" xlink:type="simple"/></inline-formula>, simultaneously to the corresponding measurements during infection (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e167" xlink:type="simple"/></inline-formula>) using <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e168" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e169" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e170" xlink:type="simple"/></inline-formula> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e171" xlink:type="simple"/></inline-formula>), and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e172" xlink:type="simple"/></inline-formula> as adjustable parameters for different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e173" xlink:type="simple"/></inline-formula>. (We employed a truncated Gaussian approximation to the Poisson probability for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e174" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1002307.s003">Fig. S3</xref>).) Model predictions again provided good fits to the data (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3B</xref> and <xref ref-type="supplementary-material" rid="pcbi.1002307.s004">Fig. S4A</xref>) indicating the ability of our model to capture experimental observations quantitatively.</p>
          <p>The data were consistent with the triphasic viral kinetics predicted by our model. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e175" xlink:type="simple"/></inline-formula> displayed an initial rise followed by a plateau and a subsequent rise (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3B</xref>). <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e176" xlink:type="simple"/></inline-formula> displayed an initial rise and a plateau. The ratio <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e177" xlink:type="simple"/></inline-formula> rose initially, attained a maximum, and then declined. In our model calculations, both <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e178" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e179" xlink:type="simple"/></inline-formula> rose in the first phase (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2</xref>), in agreement with the initial rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e180" xlink:type="simple"/></inline-formula>, which is the sum of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e181" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e182" xlink:type="simple"/></inline-formula>, in the experiments. In the second phase, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e183" xlink:type="simple"/></inline-formula> declined primarily due to infection, giving rise to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e184" xlink:type="simple"/></inline-formula>, which maintained a nearly constant sum of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e185" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e186" xlink:type="simple"/></inline-formula>, consistent with the plateau in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e187" xlink:type="simple"/></inline-formula>. In the third phase, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e188" xlink:type="simple"/></inline-formula> remained nearly constant or rose marginally, whereas <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e189" xlink:type="simple"/></inline-formula> rose significantly, in agreement with the subsequent rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e190" xlink:type="simple"/></inline-formula>. Similarly, the rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e191" xlink:type="simple"/></inline-formula> in the second phase followed by the plateau were also in agreement with the trends predicted (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2</xref>). In the first phase, however, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e192" xlink:type="simple"/></inline-formula> initially declined and then rose as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e193" xlink:type="simple"/></inline-formula> increased (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2</xref>). The data considered here were collected from day 2 post-infection (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3B</xref>), by which period pseudo-steady state between viral production and clearance is expected to be established and the initial decline of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e194" xlink:type="simple"/></inline-formula> is therefore not expected to be observed. Finally, the initial rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e195" xlink:type="simple"/></inline-formula> corresponded to the rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e196" xlink:type="simple"/></inline-formula> in the first and second phases; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e197" xlink:type="simple"/></inline-formula> had lifespans shorter than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e198" xlink:type="simple"/></inline-formula> due to virus-induced cytopathicity so that higher values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e199" xlink:type="simple"/></inline-formula> resulted in greater <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e200" xlink:type="simple"/></inline-formula>. The subsequent drop in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e201" xlink:type="simple"/></inline-formula> corresponded to the rise of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e202" xlink:type="simple"/></inline-formula> in the third phase, which increased <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e203" xlink:type="simple"/></inline-formula> and also lowered the overall rate of cell death.</p>
        </sec>
        <sec id="s2c2">
          <title>Threshold number of E2-CD81 complexes necessary for entry</title>
          <p>From the above fits, for each value of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e204" xlink:type="simple"/></inline-formula> in the range <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e205" xlink:type="simple"/></inline-formula>, we obtained a corresponding best-fit estimate of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e206" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g004">Fig. 4</xref>, <xref ref-type="supplementary-material" rid="pcbi.1002307.s010">Table S1</xref>). For example, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e207" xlink:type="simple"/></inline-formula> (95% CI: 6–13) when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e208" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e209" xlink:type="simple"/></inline-formula> (95% CI: 2–4) when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e210" xlink:type="simple"/></inline-formula>. The best-fits thus suggested that depending on the affinity of E2 for CD81, between 1 and 13 E2-CD81 complexes across a virus-cell pair were necessary for the entry of JFH-1 virions into Huh-7.5.1 cells.</p>
          <fig id="pcbi-1002307-g004" position="float">
            <object-id pub-id-type="doi">10.1371/journal.pcbi.1002307.g004</object-id>
            <label>Figure 4</label>
            <caption>
              <title>Threshold number of E2-CD81 complexes.</title>
              <p>Estimates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e211" xlink:type="simple"/></inline-formula> for different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e212" xlink:type="simple"/></inline-formula> obtained from fits of model predictions to the data of Zhong et al. <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref> (circles) and Koutsoudakis et al. <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref> (diamonds) (<xref ref-type="supplementary-material" rid="pcbi.1002307.s004">Fig. S4</xref>). Error bars are 95% confidence intervals.</p>
            </caption>
            <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.g004" xlink:type="simple"/>
          </fig>
        </sec>
        <sec id="s2c3">
          <title>Robustness of parameter estimates</title>
          <p>To test the robustness of our estimate of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e213" xlink:type="simple"/></inline-formula>, we applied our model to the analysis of two independent datasets of viral entry and kinetics in vitro. Koutsoudakis et al. <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref> exposed an equal mixture of Huh7-Lunet and Lunet/CD81 cells to Jc1 virions at two different MOIs and measured the fractions of cells infected in sub-populations with distinct CD81 expression levels at day 3 post-infection. To compare our model predictions with their data, we employed the initial CD81 distribution obtained by averaging the distributions on Huh7-Lunet and Lunet/CD81 cells (<xref ref-type="supplementary-material" rid="pcbi.1002307.s002">Fig. S2</xref>) and predicted the fraction of cells infected in cell sub-populations with distinct CD81 expression levels, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e214" xlink:type="simple"/></inline-formula>. We fixed <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e215" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e216" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e217" xlink:type="simple"/></inline-formula> to the values estimated above (<xref ref-type="table" rid="pcbi-1002307-t001">Table 1</xref>). The two initial MOIs employed would lead to different pseudo-steady states between viral production and clearance; i.e., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e218" xlink:type="simple"/></inline-formula> would still hold, but the values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e219" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e220" xlink:type="simple"/></inline-formula> would be different when the pseudo steady state is reached in the two cases. To account explicitly for the different initial MOIs employed, we therefore relaxed the pseudo-steady state approximation in our model. We obtained <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e221" xlink:type="simple"/></inline-formula>, the viral clearance rate, by fitting our model predictions without the pseudo-steady state approximation to the above data of Zhong et al. <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref> (<xref ref-type="supplementary-material" rid="pcbi.1002307.s005">Fig. S5</xref>). We then fit our predictions of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e222" xlink:type="simple"/></inline-formula> to the data of Koutsoudakis et al. <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref> with both the initial MOIs simultaneously using the appropriate initial conditions and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e223" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e224" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e225" xlink:type="simple"/></inline-formula> as adjustable parameters for different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e226" xlink:type="simple"/></inline-formula>. In effect, we assumed that the differences in the viral clones, JFH-1 and Jc1, and the cell lines, Huh7.5 and the combination of Huh7-Lunet and Lunet/CD81, affected the viral production rate and/or the infection rate.</p>
          <table-wrap id="pcbi-1002307-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1002307.t001</object-id><label>Table 1</label><caption>
              <title>Summary of model parameters and their values employed.</title>
            </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1002307-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.t001" xlink:type="simple"/><table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" colspan="1" rowspan="1">Parameter</td>
                  <td align="left" colspan="1" rowspan="1">Description</td>
                  <td align="left" colspan="1" rowspan="1">Value (95% CI)<xref ref-type="table-fn" rid="nt101">a</xref></td>
                  <td align="left" colspan="1" rowspan="1">Source</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>λ</italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Proliferation rate of target cells</td>
                  <td align="left" colspan="1" rowspan="1">0.44 (0.43–0.46) d<sup>−1</sup></td>
                  <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3A</xref>)</td>
                </tr>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>μ</italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Death rate of target cells</td>
                  <td align="left" colspan="1" rowspan="1">1.7 (1.4–2.0)×10<sup>−4</sup> d<sup>−1</sup></td>
                  <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3A</xref>)</td>
                </tr>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>δ</italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Death rate of infected cells</td>
                  <td align="left" colspan="1" rowspan="1">1.1 (0.4–1.8)×10<sup>−2</sup> d<sup>−1</sup></td>
                  <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3B</xref>)</td>
                </tr>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>β</italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Infection rate of cells with excess CD81 expression</td>
                  <td align="left" colspan="1" rowspan="1">1.2 (0.6–1.8)×10<sup>−4</sup> ml•(ffu•d)<sup>−1</sup></td>
                  <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3B</xref>)</td>
                </tr>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>ω</italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Ratio of viral production rate per cell (<italic>p</italic>) and clearance rate (<italic>c</italic>)</td>
                  <td align="left" colspan="1" rowspan="1">0.12 (0.06–0.19) ffu•ml<sup>−1</sup></td>
                  <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3B</xref>)</td>
                </tr>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>c</italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Clearance rate</td>
                  <td align="left" colspan="1" rowspan="1">23.2 d<sup>−1</sup></td>
                  <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="supplementary-material" rid="pcbi.1002307.s005">Fig. S5</xref>)</td>
                </tr>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>K<sub>D</sub></italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Equilibrium dissociation constant of the E2-CD81 binding reaction</td>
                  <td align="left" colspan="1" rowspan="1">10<sup>−4</sup>–10<sup>−5</sup> M</td>
                  <td align="left" colspan="1" rowspan="1">Varied</td>
                </tr>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>n<sub>E</sub></italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Number density of E2 molecules on HCV</td>
                  <td align="left" colspan="1" rowspan="1">2.3×10<sup>4</sup> µm<sup>−2</sup></td>
                  <td align="left" colspan="1" rowspan="1">
                    <xref ref-type="bibr" rid="pcbi.1002307-Yu1">[53]</xref>
                  </td>
                </tr>
                <tr>
                  <td align="left" colspan="1" rowspan="1">
                    <italic>A</italic>
                  </td>
                  <td align="left" colspan="1" rowspan="1">Virus-cell contact area</td>
                  <td align="left" colspan="1" rowspan="1">1.3×10<sup>−3</sup> µm<sup>2</sup></td>
                  <td align="left" colspan="1" rowspan="1">
                    <xref ref-type="bibr" rid="pcbi.1002307-Sougrat1">[54]</xref>
                  </td>
                </tr>
              </tbody>
            </table></alternatives><table-wrap-foot>
              <fn id="nt101">
                <label>a</label>
                <p>Typical values employed. Variations are indicated in the text and in figure legends.</p>
              </fn>
            </table-wrap-foot></table-wrap>
          <p>Model predictions again provided excellent fits to the data (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3C</xref> and <xref ref-type="supplementary-material" rid="pcbi.1002307.s004">Fig. S4B</xref>). For CD81 expression levels <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e227" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e228" xlink:type="simple"/></inline-formula> remained negligible for both MOIs, indicating that these subpopulations were refractory to infection. For higher expression levels, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e229" xlink:type="simple"/></inline-formula> increased with CD81 expression and reached a plateau at an expression level of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e230" xlink:type="simple"/></inline-formula>, beyond which viral entry was not limited by CD81. The plateau attained different values for the two MOIs, as expected from the different underlying viral kinetics. With MOI of 5, ∼90% of the cells with excess CD81 were infected by day 3, whereas with MOI of 1, ∼50% of the cells with excess CD81 were infected. The resulting estimates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e231" xlink:type="simple"/></inline-formula> were in close agreement with the estimates obtained above (<xref ref-type="fig" rid="pcbi-1002307-g004">Fig. 4</xref> and <xref ref-type="supplementary-material" rid="pcbi.1002307.s011">Table S2</xref>), giving us confidence in our model and our estimates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e232" xlink:type="simple"/></inline-formula>. We note that model predictions of the total percentage of cells infected, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e233" xlink:type="simple"/></inline-formula>, at MOI 5 and 1 (∼31% and ∼23%, respectively) were lower than the corresponding measurements (57% and 29%). We found that altering the initial mixture (1∶4 Huh7-Lunet and Lunet/CD81 cells) or the initial distribution of CD81 expression brought our predictions (∼50% and ∼30%, respectively) close to the experiments. Fits to the data and the resulting estimates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e234" xlink:type="simple"/></inline-formula> remained unaltered; the only differences were in the estimates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e235" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e236" xlink:type="simple"/></inline-formula>, again indicating the robustness of the estimates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e237" xlink:type="simple"/></inline-formula>.</p>
          <p>We considered finally the experiments of Tscherne et al. <xref ref-type="bibr" rid="pcbi.1002307-Tscherne1">[14]</xref>, where the fraction of Huh 7.5 cells infected with J6/JFH virus was measured as a function of time following the onset of infection. We solved our model equations without any adjustable parameters and with the appropriate initial conditions and predicted the time-evolution of the fraction of cells infected, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e238" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3D</xref>). Following the onset of infection, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e239" xlink:type="simple"/></inline-formula> increased and reached a maximum of 90% at day 5 post-infection. Subsequently, cells refractory to infection began to outgrow the susceptible population and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e240" xlink:type="simple"/></inline-formula> decreased, reaching ∼20% by day 17 post-infection. Our model captured the measured evolution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e241" xlink:type="simple"/></inline-formula> quantitatively (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3D</xref> and <xref ref-type="supplementary-material" rid="pcbi.1002307.s004">Fig. S4C</xref>). The agreement between model predictions without any adjustable parameters and experimental observations represented a successful validation of our model as well as the parameter estimates obtained above.</p>
        </sec>
      </sec>
    </sec>
    <sec id="s3">
      <title>Discussion</title>
      <p>Analysis of experimental data using mathematical models has provided crucial insights into disease pathogenesis and the effectiveness of drugs and established guidelines for rational optimization of therapy for HCV infection <xref ref-type="bibr" rid="pcbi.1002307-Neumann1">[21]</xref>–<xref ref-type="bibr" rid="pcbi.1002307-Hsu1">[31]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-DebRoy1">[33]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Krishnan1">[34]</xref>. The recent development of cell culture systems that allow persistent HCV infection in vitro <xref ref-type="bibr" rid="pcbi.1002307-Wakita1">[35]</xref>–<xref ref-type="bibr" rid="pcbi.1002307-Ploss2">[38]</xref> has yielded a wealth of new data on HCV replication, evolution, and the impact of drugs. Analysis of this data is expected to provide further insights into HCV pathogenesis and outcomes of therapy, but has been precluded by the lack of mathematical models of HCV viral kinetics in vitro. Indeed, significant efforts are underway to construct models of the intracellular replication and evolution of HCV with the aim of elucidating the activity of direct acting antiviral drugs <xref ref-type="bibr" rid="pcbi.1002307-Guedj2">[39]</xref>–<xref ref-type="bibr" rid="pcbi.1002307-Dahari3">[41]</xref>. Here, we have constructed a mathematical model of HCV viral kinetics in vitro. Applying it to the analysis of data from several recent cell culture studies, we obtained quantitative insights into the molecular requirements of HCV entry. We estimated that depending on the binding affinity of E2 and CD81, between 1 and 13 E2-CD81 complexes are necessary for HCVcc entry into human hepatoma-derived cells.</p>
      <p>Our estimate provides a quantitative guideline for the optimal usage of drugs and vaccines that target the E2-CD81 interaction: A potent drug or vaccine must ensure that not more than 1–13 E2-CD81 complexes are formed across a virus-cell pair in order to prevent viral entry. This guideline assumes significance as drugs that target the E2-CD81 interaction are under development <xref ref-type="bibr" rid="pcbi.1002307-Lemon1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Zeisel1">[12]</xref> and may become part of future treatments involving direct acting antiviral agents that seek to overcome the limitations of the current interferon-ribavirin-based treatments <xref ref-type="bibr" rid="pcbi.1002307-Hofmann1">[42]</xref>. Further, a recent analysis of the HCV quasispecies in six patients who underwent liver transplantation revealed that viral strains capable of more efficient entry, achieved through modulation of the CD81 dependence of viral entry, were selected following liver transplantation <xref ref-type="bibr" rid="pcbi.1002307-FafiKremer1">[8]</xref>. Blocking E2-CD81 interactions effectively, for which our estimate presents a quantitative criterion, may thus be a promising avenue to prevent graft reinfection following liver transplantation.</p>
      <p>In an earlier study, Koutsoudakis et al. <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref> estimated that a cell must express &gt;70000 CD81 molecules to allow HCV entry. This threshold was identified as follows. In independent experiments, cells with widely varying distributions of CD81 were exposed to HCV at low MOI in culture and the percentage of cells infected at day 5 was measured. This latter percentage was found to correlate well with the percentage of cells initially expressing &gt;70000 CD81 molecules/cell. For instance, with Huh7.5 cells, the percentage of cells infected at day 5 was 91.5 and the percentage expressing &gt;70000 CD81 molecules/cell at day 0 was 93, and with Huh7-Lunet cells, which express fewer CD81 molecules than Huh7.5 cells, the percentages were 11.2 and 17, respectively. Based on this correlation, Koutsoudakis et al. suggested 70000 CD81 molecules/cell as the threshold for entry. Our present analysis suggests that the underlying viral kinetics may render this estimate an upper bound. Virus-induced cytopathicity in culture would result in the loss of susceptible cells and therefore a continuous decrease in the frequency of susceptible cells with time. Consequently, the percentage of cells susceptible initially is expected to be higher than the percentage of cells susceptible–and hence even higher than the percentage infected–at day 5 post-infection. The higher percentage of cells susceptible initially would therefore imply a threshold smaller than 70000 molecules/cell. This is also evident in the experiments of Koutsoudakis et al., where cells with lower CD81 expression (MFI∼50) than 70000 molecules/cell (MFI∼100) were infected (see <xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3C</xref>). From our analysis, we identified the threshold number of E2-CD81 complexes and not CD81 molecules necessary for entry. Because stochastic events can result in the formation of the requisite number of complexes, cells expressing few CD81 molecules have small but nonzero susceptibilities to infection. Indeed, we found using parameters employed in <xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3D</xref> that a small percentage of cells expressing as few as ∼10000 CD81 molecules was infected by day 5. More recently, Zhang et al. <xref ref-type="bibr" rid="pcbi.1002307-Zhang1">[18]</xref> have argued that a substantially smaller expression level than suggested by Koutsoudakis et al. may suffice for entry and that CD81 may also be necessary, perhaps at higher expression levels, for post-entry events. Our model does not distinguish between entry and post-entry requirements of CD81. Our estimate of 1–13 E2-CD81 complexes defines successful infection of a cell and combines the requirements for entry and any post-entry steps <xref ref-type="bibr" rid="pcbi.1002307-Brazzoli1">[17]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Zhang1">[18]</xref>.</p>
      <p>Our model yielded good fits to data with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e242" xlink:type="simple"/></inline-formula> in the range <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e243" xlink:type="simple"/></inline-formula>, which is higher than the value, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e244" xlink:type="simple"/></inline-formula>, determined using recombinant E2 and soluble CD81 <xref ref-type="bibr" rid="pcbi.1002307-Nakajima1">[43]</xref>. (Fits with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e245" xlink:type="simple"/></inline-formula> were poor (not shown).) This discrepancy may be because the binding affinity when the proteins are in solution may be different from that when the proteins are restricted to membranes <xref ref-type="bibr" rid="pcbi.1002307-Baksh1">[44]</xref>, recombinant E2 may not accurately mimic the true E2-CD81 interaction <xref ref-type="bibr" rid="pcbi.1002307-Flint1">[45]</xref>, and/or only a fraction of the CD81 may lie outside tetraspanin-enriched microdomains and/or be associated with CLDN1 and therefore available for binding E2 <xref ref-type="bibr" rid="pcbi.1002307-Harris1">[10]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-RochaPerugini1">[46]</xref>. The E2-CD81 binding affinity in situ remains to be determined. Our model yielded best-fit values of the threshold number of complexes, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e246" xlink:type="simple"/></inline-formula>, that decreased as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e247" xlink:type="simple"/></inline-formula> increased (<xref ref-type="fig" rid="pcbi-1002307-g004">Fig. 4</xref>). For a given CD81 expression level, the mean number of E2-CD81 complexes formed decreased as <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e248" xlink:type="simple"/></inline-formula> increased, lowering susceptibility (Eqs. (4) and (5)). Decreasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e249" xlink:type="simple"/></inline-formula> restored this susceptibility (<xref ref-type="fig" rid="pcbi-1002307-g002">Fig. 2B</xref> inset and <xref ref-type="supplementary-material" rid="pcbi.1002307.s006">Fig. S6</xref>), thus ensuring that the resulting viral kinetics was conserved and in agreement with data. This does not imply, however, that viral strains with lower E2-CD81 affinity (higher <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e250" xlink:type="simple"/></inline-formula>) would require fewer E2-CD81 complexes for entry. On the contrary, given a value of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e251" xlink:type="simple"/></inline-formula>, our model predicts that a cell would be less susceptible to entry of viral strains with higher <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e252" xlink:type="simple"/></inline-formula>.</p>
      <p>Our model was designed to mimic experiments that examined the influence of CD81 expression on viral entry and kinetics <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref>–<xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref>. In these experiments, cells with high CD81 expression were preferentially infected and lost due to virus-induced cytopathicity, and cells with low CD81 expression, refractory to infection, eventually dominated the culture, suggesting that CD81 expression limited entry. Accordingly, our model assumed that other entry receptors were not limiting. Our model then predicted triphasic viral kinetics in vitro, in agreement with experiments. We note that the origins of the triphasic pattern here are distinct from the triphasic viral load decline in some patients undergoing combination therapy, the latter due to liver homeostatic mechanisms <xref ref-type="bibr" rid="pcbi.1002307-Dahari1">[25]</xref>. Further, the triphasic kinetics is a short-term phenomenon (∼2–3 weeks). Over longer periods, viral evolution may alter the kinetics substantially <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref>, which our model does not consider. Nonetheless, our model can be readily adapted to the scenario where a receptor other than CD81 is limiting and may thus serve to quantify the requirements of that receptor for HCV entry.</p>
      <p>We recognize a few additional simplifications in our model. First, our model ignored cell-cell transmission of infection. CD81 appears to be necessary for direct cell-cell transmission <xref ref-type="bibr" rid="pcbi.1002307-Brimacombe1">[47]</xref>. If the susceptibility of a cell to cell-cell transmission depends on CD81 expression in a manner similar to its susceptibility to viral entry, which remains to be ascertained, then we can show that our model with the pseudo-steady state approximation, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e253" xlink:type="simple"/></inline-formula>, implicitly accounts for cell-cell transmission: the net infection rate from both modes, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e254" xlink:type="simple"/></inline-formula>, is in agreement with our model (Eq. (1)) with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e255" xlink:type="simple"/></inline-formula> an effective infection rate constant that lumps the rate constants of infection by free virions, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e256" xlink:type="simple"/></inline-formula>, and cell-cell transmission, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e257" xlink:type="simple"/></inline-formula>. Second, our model assumes that reaction equilibrium is attained rapidly compared to viral entry and that the diffusion of CD81 on the target cells continually replenishes the free CD81 in the virus-cell contact region lost due to binding. Accordingly, our model predicts an upper bound on the mean number of E2-CD81 complexes formed in the contact region. Thus, if CD81 diffusion or its binding with E2 were rate limiting, a threshold smaller than 1–13 E2-CD81 complexes is expected to describe the data we considered. Finally, we ignored the splitting of cell culture at confluence. We employed the data at day 3 post-infection from Koutsoudakis et al. <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref>, when cells are not expected to have reached confluence. Further, the best-fit parameter estimates obtained from the data of Koutsoudakis et al. <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref> were close to those from Zhong et al. <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref> (<xref ref-type="fig" rid="pcbi-1002307-g004">Fig. 4</xref>). Also, accounting for splitting did not significantly alter our comparisons with the data of Tscherne et al. <xref ref-type="bibr" rid="pcbi.1002307-Tscherne1">[14]</xref> so long as the splitting was performed after day 5 post-infection (<xref ref-type="supplementary-material" rid="pcbi.1002307.s007">Fig. S7</xref>). Also, including a logistic term to limit the proliferation of cells as they approached confluence did not alter our parameter estimates significantly (not shown). Nonetheless, that model predictions described several independent experimental observations quantitatively indicated that even with the above simplifications our model captured the essential features of HCV viral kinetics in vitro successfully. At the same time, the simplifications restricted model parameters to a number that allowed robust parameter estimation through fits to available data.</p>
    </sec>
    <sec id="s4" sec-type="methods">
      <title>Methods</title>
      <sec id="s4a">
        <title>Model of HCV kinetics in vitro</title>
        <p>We considered <italic>in vitro</italic> experiments where a population of uninfected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e258" xlink:type="simple"/></inline-formula>, is exposed to a population of HCVcc virions, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e259" xlink:type="simple"/></inline-formula>. We divided the cells into <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e260" xlink:type="simple"/></inline-formula> subpopulations, denoted <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e261" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e262" xlink:type="simple"/></inline-formula>, with cells in each subpopulation expressing CD81 in a range <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e263" xlink:type="simple"/></inline-formula> around <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e264" xlink:type="simple"/></inline-formula> molecules per unit area. At the start of infection (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e265" xlink:type="simple"/></inline-formula>), the variation of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e266" xlink:type="simple"/></inline-formula> with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e267" xlink:type="simple"/></inline-formula> was determined from a known distribution, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e268" xlink:type="simple"/></inline-formula>, of CD81 expression levels across cells (<xref ref-type="fig" rid="pcbi-1002307-g001">Fig. 1</xref>). The following equations described the ensuing viral kinetics (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e269" xlink:type="simple"/></inline-formula>):<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e270" xlink:type="simple"/><label>(1)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e271" xlink:type="simple"/><label>(2)</label></disp-formula><disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e272" xlink:type="simple"/><label>(3)</label></disp-formula>Here, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e273" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e274" xlink:type="simple"/></inline-formula> are the proliferation and death rates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e275" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e276" xlink:type="simple"/></inline-formula> is the infection rate of cells expressing excess CD81. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e277" xlink:type="simple"/></inline-formula> is the death rate of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e278" xlink:type="simple"/></inline-formula>. Following observations of HCV-induced cell cycle arrest in vitro <xref ref-type="bibr" rid="pcbi.1002307-Walters1">[32]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Kannan1">[48]</xref>, we neglected the proliferation of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e279" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e280" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e281" xlink:type="simple"/></inline-formula> are the per cell production rate and the clearance rate of free virions, respectively. Here, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e282" xlink:type="simple"/></inline-formula> represents the combined rate of the natural degradation of virions, the loss of viral infectivity, and the loss of virions due to entry and attachment <xref ref-type="bibr" rid="pcbi.1002307-Beauchemin1">[49]</xref>, <xref ref-type="bibr" rid="pcbi.1002307-Sabahi1">[50]</xref>. For simplicity, we assumed <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e283" xlink:type="simple"/></inline-formula> to be a constant.</p>
        <p>To determine <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e284" xlink:type="simple"/></inline-formula>, we considered a cell <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e285" xlink:type="simple"/></inline-formula>, with CD81 expression level <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e286" xlink:type="simple"/></inline-formula>, closely apposed to a virion with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e287" xlink:type="simple"/></inline-formula> E2 molecules per unit area. We assumed, as with HIV <xref ref-type="bibr" rid="pcbi.1002307-Mulampaka1">[20]</xref>, that the E2-CD81 interactions across the virus-cell interface attain equilibrium well before viral entry. If <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e288" xlink:type="simple"/></inline-formula> is the surface density of E2-CD81 complexes, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e289" xlink:type="simple"/></inline-formula> that of unbound CD81 and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e290" xlink:type="simple"/></inline-formula> that of unbound E2 molecules in the contact area, then at equilibrium <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e291" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e292" xlink:type="simple"/></inline-formula> is the equilibrium dissociation constant of E2-CD81 complexes when the proteins are restricted to membranes. From Bell's analysis, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e293" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e294" xlink:type="simple"/></inline-formula> is the equilibrium dissociation constant when the proteins are in solution and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e295" xlink:type="simple"/></inline-formula> is the encounter distance between the proteins for bond formation <xref ref-type="bibr" rid="pcbi.1002307-Bell1">[51]</xref>. The virus-cell contact area, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e296" xlink:type="simple"/></inline-formula>, is small compared to the surface area of the cell. Further, free CD81 can diffuse on the cell membrane and therefore be recruited to the contact area. Consequently, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e297" xlink:type="simple"/></inline-formula> is expected not to decrease substantially below <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e298" xlink:type="simple"/></inline-formula>, as suggested also by an independent reaction-diffusion model <xref ref-type="bibr" rid="pcbi.1002307-Wu1">[52]</xref>. In contrast, the viral surface area is comparable to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e299" xlink:type="simple"/></inline-formula> and assuming E2 to be less mobile than CD81, it follows that the surface density of E2 in the contact area obeys the species balance equation: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e300" xlink:type="simple"/></inline-formula>. Under the latter two constraints, the mean number of complexes formed across the virus-cell contact at equilibrium, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e301" xlink:type="simple"/></inline-formula>, is given by<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e302" xlink:type="simple"/><label>(4)</label></disp-formula></p>
        <p>We recognized next that the E2 expression level on the virion and the virus-cell contact area are subject to stochastic variations. We assumed therefore that the number of complexes formed during a virus-cell contact, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e303" xlink:type="simple"/></inline-formula>, follows a Poisson distribution with mean <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e304" xlink:type="simple"/></inline-formula>. Viral entry (and subsequently infection) occurred if <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e305" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e306" xlink:type="simple"/></inline-formula> is the threshold number of E2-CD81 complexes necessary for HCV entry. The probability that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e307" xlink:type="simple"/></inline-formula>,<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e308" xlink:type="simple"/><label>(5)</label></disp-formula>thus yielded the relative susceptibility to infection of a cell with CD81 expression level <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e309" xlink:type="simple"/></inline-formula>. (The Poisson distribution does allow <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e310" xlink:type="simple"/></inline-formula> to exceed the limit of 180 set by the number of E2 molecules present on a virion, but in all our calculations <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e311" xlink:type="simple"/></inline-formula> remained fewer than 30 (<xref ref-type="supplementary-material" rid="pcbi.1002307.s008">Fig. S8</xref>) so that the probability that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e312" xlink:type="simple"/></inline-formula> was negligibly small.)</p>
        <p>Equations (1)–(5) yielded a model of HCV kinetics in vitro that accounted explicitly for the dependence of viral entry on the CD81 expression level on cells.</p>
      </sec>
      <sec id="s4b">
        <title>Model parameters and calculations</title>
        <p>We solved model equations using a computer program written in MATLAB and computed quantities measured experimentally, namely, the time-evolution of the populations of uninfected and infected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e313" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e314" xlink:type="simple"/></inline-formula>, the viral titre, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e315" xlink:type="simple"/></inline-formula>, the fraction of cells infected, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e316" xlink:type="simple"/></inline-formula>, the fraction of cells infected within each subpopulation, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e317" xlink:type="simple"/></inline-formula>, and the populations of viable and dead cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e318" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e319" xlink:type="simple"/></inline-formula>, respectively.</p>
        <p>We employed the following parameter values and initial conditions: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e320" xlink:type="simple"/></inline-formula> corresponding to 180 E2 molecules on a virion with average diameter 50 nm <xref ref-type="bibr" rid="pcbi.1002307-Yu1">[53]</xref>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e321" xlink:type="simple"/></inline-formula>, corresponding to a virus-cell contact radius of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e322" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002307-Sougrat1">[54]</xref>; the target cell diameter was <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e323" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1002307-Brazzoli1">[17]</xref>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e324" xlink:type="simple"/></inline-formula> was varied over the range <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e325" xlink:type="simple"/></inline-formula> (see above). The initial CD81 expression was assumed to follow the log-normal distribution, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e326" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e327" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e328" xlink:type="simple"/></inline-formula> were the mean and standard deviation of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e329" xlink:type="simple"/></inline-formula>. For comparisons with experimental data, the initial distributions were obtained from measurements (<xref ref-type="supplementary-material" rid="pcbi.1002307.s002">Fig. S2</xref>; see below). Thus, the initial cell subpopulations, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e330" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e331" xlink:type="simple"/></inline-formula> was the total initial target cell population. We divided the range of CD81 expression levels into <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e332" xlink:type="simple"/></inline-formula> intervals, which determined <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e333" xlink:type="simple"/></inline-formula>; finer discretisation did not improve the accuracy of our solution (<xref ref-type="supplementary-material" rid="pcbi.1002307.s001">Fig. S1</xref>). The remaining parameters, estimated from fits to data, are listed in <xref ref-type="supplementary-material" rid="pcbi.1002307.s010">Tables S1</xref> and <xref ref-type="supplementary-material" rid="pcbi.1002307.s011">S2</xref>. We have summarized model parameters in <xref ref-type="table" rid="pcbi-1002307-t001">Table 1</xref>.</p>
      </sec>
      <sec id="s4c">
        <title>Data and fitting</title>
        <p>We considered data from three recently published cell culture studies of HCV kinetics. First, we considered data of Zhong et al. <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref>, where Huh-7.5.1 cells were exposed to JFH-1 virions and the kinetics of infection followed for 21 d. Specifically, we employed the data of the time-evolution of the supernatant infectivity, the population of attached (viable) cells, and the ratio of the populations of floating (dead) and attached cells, the latter two datasets with mock infection as well as with HCVcc infection (<xref ref-type="supplementary-material" rid="pcbi.1002307.s001">Fig. S1</xref> in <xref ref-type="bibr" rid="pcbi.1002307-Zhong1">[15]</xref>). Second, we considered data of Koutsoudakis et al. <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref>, where a 1∶1 mixture of Huh7-Lunet and Lunet/CD81 cells was exposed to HCVcc Venus-Jc1 virus and the fractions of cells infected in subpopulations with distinct CD81 expression levels were measured after 72 h. The initial viral population was at an MOI of ∼5 and ∼1 TCID<sub>50</sub>/cell (where TCID<sub>50</sub> is the 50% tissue culture infective dose), respectively, in two independent experiments (Fig. 5 in <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref>). Third, we considered the data of Tscherne et al. <xref ref-type="bibr" rid="pcbi.1002307-Tscherne1">[14]</xref>, where Huh7.5 cells were exposed to J6/JFH virus and the time-evolution of the fraction of cells infected as well as of the distribution of CD81 expression levels across cells was followed for 17 d (Fig. 8 in <xref ref-type="bibr" rid="pcbi.1002307-Tscherne1">[14]</xref>).</p>
        <p>The CD81 expression on cells is usually measured in terms of fluorescent intensity. To convert the measurements to CD81 surface densities, we adopted the following procedure. Measured distributions of the CD81 expression level on Huh-7.5 (silRR) cells were digitized from Zhang et al. <xref ref-type="bibr" rid="pcbi.1002307-Zhang2">[55]</xref> and on Huh-7.5 cells from Koutsoudakis et al. <xref ref-type="bibr" rid="pcbi.1002307-Koutsoudakis1">[13]</xref>. The log-normal distribution, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e334" xlink:type="simple"/></inline-formula>, yielded good fits to the data (<xref ref-type="supplementary-material" rid="pcbi.1002307.s009">Fig. S9</xref>). The best-fit parameter values (95% CI) were <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e335" xlink:type="simple"/></inline-formula> = 4.29 (4.27–4.31) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e336" xlink:type="simple"/></inline-formula> = 0.45 (0.43–0.47) for the data of Zhang et al. and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e337" xlink:type="simple"/></inline-formula> = 6.1 (6.07–6.12) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e338" xlink:type="simple"/></inline-formula> = 0.7 (0.67–0.72) for the data of Koutsoudakis et al. Because the same cell lines were used, the underlying distributions of CD81 expression are expected to be similar in the two experiments. The differences in the reported fluorescence intensities may therefore be attributed to different conversions of CD81 surface density to fluorescence intensity in the two measurements. To unravel the underlying distribution, we assumed that log fluorescence intensity was linearly proportional to log CD81 surface density (or that the fluorescence intensity had a power law dependence on the surface density). Thus, a cell with CD81 surface density <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e339" xlink:type="simple"/></inline-formula> would yield a fluorescence intensity <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e340" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e341" xlink:type="simple"/></inline-formula> in the measurements of Zhang et al. and Koutsoudakis et al., respectively, such that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e342" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e343" xlink:type="simple"/></inline-formula>, where <italic>a</italic>, <italic>b</italic>, <italic>c</italic>, and <italic>d</italic> are constants. To determine the latter constants, we employed the following observations: The mean surface density of CD81 for the Huh-7 cell line is 2×10<sup>5</sup> molecules/cell <xref ref-type="bibr" rid="pcbi.1002307-Cormier1">[3]</xref>, which corresponded to a fluorescence intensity of 48 units in the measurements of Zhang et al., so that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e344" xlink:type="simple"/></inline-formula>. Also, Koutsoudakis et al. measured the number of CD81 molecules/cell corresponding to a fluorescence intensity of 100 units and found it to be 7×10<sup>4</sup> molecules/cell, so that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e345" xlink:type="simple"/></inline-formula>. Further the above relationship between fluorescence intensity and CD81 expression also implied that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e346" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e347" xlink:type="simple"/></inline-formula>. Solving the latter equations using the best-fit parameters above, we obtained <italic>a</italic> = 2.8, <italic>b</italic> = 2.43, <italic>c</italic> = 3.96 and <italic>d</italic> = 1.56, which enabled conversion of measured fluorescence intensities to CD81 surface densities, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e348" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1002307.s002">Fig. S2</xref>). The measured distributions in terms of counts versus fluorescence intensities were then converted to probability distributions, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e349" xlink:type="simple"/></inline-formula> versus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e350" xlink:type="simple"/></inline-formula>, by normalizing the counts such that the areas under the <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e351" xlink:type="simple"/></inline-formula> versus <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e352" xlink:type="simple"/></inline-formula> curves equalled unity. The resulting distributions (<xref ref-type="supplementary-material" rid="pcbi.1002307.s002">Fig. S2</xref>) were employed as the initial CD81 distributions for our fits to data (<xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3</xref>).</p>
        <p>We digitized data using Engauge digitizer and fit model predictions to data using the nonlinear regression tool NLINFIT in MATLAB.</p>
      </sec>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pcbi.1002307.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s001" xlink:type="simple">
        <label>Figure S1</label>
        <caption>
          <p><bold>Sensitivity to model parameters.</bold> Time-evolution of (A) uninfected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e353" xlink:type="simple"/></inline-formula>, (B) infected cells, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e354" xlink:type="simple"/></inline-formula>, (C) viral load, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e355" xlink:type="simple"/></inline-formula>, and (D) the fraction of cells infected, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e356" xlink:type="simple"/></inline-formula>, obtained by varying (I) the equilibrium dissociation constant, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e357" xlink:type="simple"/></inline-formula> = 1.7×10<sup>−5</sup> M (thick solid line), 3.3×10<sup>−5</sup> M (thin solid line), and 1.7×10<sup>−4</sup> M (dashed line), (II) the mean of the log initial CD81 expression level, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e358" xlink:type="simple"/></inline-formula> = 29.8 (thick solid line), 31.8 (thin solid line), and 33.8 (dashed line), (III) the initial viral load, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e359" xlink:type="simple"/></inline-formula> = 40 ffu·ml<sup>−1</sup> (thick solid line), 400 ffu·ml<sup>−1</sup> (thin solid line), and 4000 ffu·ml<sup>−1</sup> (dashed line), (IV) the infection rate constant, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e360" xlink:type="simple"/></inline-formula> = 1.2×10<sup>−3</sup> ml·(ffu·d)<sup>−1</sup> (thick solid line), 1.2×10<sup>−4</sup> ml·(ffu·d)<sup>−1</sup> (thin solid line), and 1.2×10<sup>−5</sup> ml·(ffu·d)<sup>−1</sup> (dashed line), (V) the viral production rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e361" xlink:type="simple"/></inline-formula> = 0.278 ffu·(ml·d)<sup>−1</sup> (thick solid line), 2.78 ffu·(ml·d)<sup>−1</sup> (thin solid line), and 27.8 ffu·(ml·d)<sup>−1</sup> (dashed line), and (VI) the number of cell sub-populations, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e362" xlink:type="simple"/></inline-formula> = 40 (thick solid line), 80 (thin solid line), and 120 (dashed line). (The three curves in (VI) are indistinguishable.)</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s002" xlink:type="simple">
        <label>Figure S2</label>
        <caption>
          <p><bold>Initial distribution of the CD81 expression level on target cells.</bold> Distribution of the CD81 expression level on (A) Huh-7.5 cells and (B) Huh7-Lunet cells (diamonds) and Lunet/CD81 cells (circles) obtained by digitizing data from Koutsoudakis et al. (2007) J Virol 81:588–598 and converting fluorescence intensities to CD81 surface densities (<xref ref-type="sec" rid="s4">Methods</xref>).</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s003" xlink:type="simple">
        <label>Figure S3</label>
        <caption>
          <p><bold>Approximating the Poisson distribution with a truncated Gaussian distribution.</bold> Model predictions of the susceptibility of cells using the Poisson distribution, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e363" xlink:type="simple"/></inline-formula> (dashed line), and an equivalent truncated Gaussian distribution with mean <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e364" xlink:type="simple"/></inline-formula> and standard deviation <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e365" xlink:type="simple"/></inline-formula>, which yields <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e366" xlink:type="simple"/></inline-formula> (solid line), where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e367" xlink:type="simple"/></inline-formula> is the complementary error function, for different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e368" xlink:type="simple"/></inline-formula> and for (A) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e369" xlink:type="simple"/></inline-formula> = 1.7×10<sup>−5</sup> M and (B) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e370" xlink:type="simple"/></inline-formula> = 3.3×10<sup>−4</sup> M.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s004" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s004" xlink:type="simple">
        <label>Figure S4</label>
        <caption>
          <p><bold>Comparisons of model predictions with data using different values of </bold><bold><italic>K<sub>D</sub></italic></bold><bold>.</bold> (A) The fit in <xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3B</xref> repeated with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e371" xlink:type="simple"/></inline-formula> = 1.7×10<sup>−5</sup> M (thick solid line), 3.3×10<sup>−5</sup> M (thin solid line), 1.7×10<sup>−4</sup> M (dashed line), and 3.3×10<sup>−4</sup> M (dotted line). The resulting best-fit parameter estimates are in <xref ref-type="supplementary-material" rid="pcbi.1002307.s010">Table S1</xref>. (The fits for different <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e372" xlink:type="simple"/></inline-formula> nearly overlap and are indistinguishable.) (B) Fits in <xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3C</xref> repeated with the above values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e373" xlink:type="simple"/></inline-formula>. The resulting best-fit parameter estimates are in <xref ref-type="supplementary-material" rid="pcbi.1002307.s011">Table S2</xref>. (C) The comparison in <xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3D</xref> repeated with the above values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e374" xlink:type="simple"/></inline-formula> and other parameter values in <xref ref-type="supplementary-material" rid="pcbi.1002307.s010">Table S1</xref>.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s005" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s005" xlink:type="simple">
        <label>Figure S5</label>
        <caption>
          <p><bold>Fits without the pseudo-steady state approximation.</bold> The pseudo-steady state approximation is relaxed and our model predictions (Eqs. (1)–(5)) are fit to the data in <xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3B</xref> using the parameter estimates in <xref ref-type="supplementary-material" rid="pcbi.1002307.s010">Table S1</xref> and with viral clearance rate <italic>c</italic> as an adjustable parameter. Initial conditions used are: <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e375" xlink:type="simple"/></inline-formula> = 3.7×10<sup>4</sup> cells; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e376" xlink:type="simple"/></inline-formula> = 400 ffu·ml<sup>−1</sup>; <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e377" xlink:type="simple"/></inline-formula> = <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e378" xlink:type="simple"/></inline-formula> = 0. The resulting estimates of <italic>c</italic> are 21.4, 22.7, 23.2 and 23.8 d<sup>−1</sup> for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e379" xlink:type="simple"/></inline-formula>1.7×10<sup>−5</sup>, 3.3×10<sup>−5</sup>, 1.7×10<sup>−4</sup>, and 3.3×10<sup>−4</sup> M, respectively. (The fits for different <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e380" xlink:type="simple"/></inline-formula> nearly overlap and are indistinguishable.)</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s006" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s006" xlink:type="simple">
        <label>Figure S6</label>
        <caption>
          <p><bold>Susceptibility of cells predicted using different best-fit parameter combinations.</bold> Dependence of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e381" xlink:type="simple"/></inline-formula> on CD81 expression predicted using the parameter combinations in (A) <xref ref-type="supplementary-material" rid="pcbi.1002307.s010">Table S1</xref> and (B) <xref ref-type="supplementary-material" rid="pcbi.1002307.s011">Table S2</xref> where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e382" xlink:type="simple"/></inline-formula> = 1.7×10<sup>−5</sup> M (thick solid line), 3.3×10<sup>−5</sup> M (thin solid line), 1.7×10<sup>−4</sup> M (dashed line), and 3.3×10<sup>−4</sup> M (dotted line).</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s007" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s007" xlink:type="simple">
        <label>Figure S7</label>
        <caption>
          <p><bold>Influence of splitting of cell culture at confluence.</bold> Model predictions of the fraction of cells infected without splitting (thick line), splitting at day 6 and day 12 (thin line), and splitting at day 8 and day 12 (dashed line) after the onset of infection compared with the data in <xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3D</xref> (symbols). Parameters used are the same as in <xref ref-type="fig" rid="pcbi-1002307-g003">Fig. 3D</xref>.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s008" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s008" xlink:type="simple">
        <label>Figure S8</label>
        <caption>
          <p><bold>Mean number and probability of formation of E2-CD81 complexes.</bold> (A) Model predictions of the mean number of E2-CD81 complexes formed, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e383" xlink:type="simple"/></inline-formula>, as a function of CD81 expression for <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e384" xlink:type="simple"/></inline-formula> = 1.7×10<sup>−5</sup> M (solid line), 3.3×10<sup>−5</sup> M (dashed line), 1.7×10<sup>−4</sup> M (dashed-dotted line), and 3.3×10<sup>−4</sup> M (dotted line). (B) Model predictions of the Poisson probability of forming <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e385" xlink:type="simple"/></inline-formula> E2-CD81 complexes (Eq. (5)) when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e386" xlink:type="simple"/></inline-formula> (solid line) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e387" xlink:type="simple"/></inline-formula> (dashed line).</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s009" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s009" xlink:type="simple">
        <label>Figure S9</label>
        <caption>
          <p><bold>Conversion of fluorescence intensity to CD81 expression.</bold> Measured distributions of the CD81 expression level on Huh-7.5 (silRR) cells digitized from Zhang et al. (2004) J Virol 78:1448–1445 (diamonds) and Huh-7.5 cells from Koutsoudakis et al. (2007) J Virol 81:588–598 (triangles). Lines are best-fits of the log-normal distribution, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e388" xlink:type="simple"/></inline-formula>, to the data. The best-fit parameter values (95% CI) are <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e389" xlink:type="simple"/></inline-formula> = 4.29 (4.27–4.31) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e390" xlink:type="simple"/></inline-formula> = 0.45 (0.43–0.47) for the data of Zhang et al. and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e391" xlink:type="simple"/></inline-formula> = 6.1 (6.07–6.12) and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1002307.e392" xlink:type="simple"/></inline-formula> = 0.7 (0.67–0.72) for the data of Koutsoudakis et al.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s010" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s010" xlink:type="simple">
        <label>Table S1</label>
        <caption>
          <p><bold>Estimates of model parameters obtained from fits of model predictions to the data in </bold><xref ref-type="fig" rid="pcbi-1002307-g003"><bold>Figs. 3B</bold></xref><bold> and S4A.</bold> 95% confidence intervals are indicated in brackets.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pcbi.1002307.s011" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1002307.s011" xlink:type="simple">
        <label>Table S2</label>
        <caption>
          <p><bold>Estimates of model parameters obtained from fits of model predictions to the data in </bold><xref ref-type="fig" rid="pcbi-1002307-g003"><bold>Figs. 3C</bold></xref><bold> and S4B.</bold> 95% confidence intervals are indicated in brackets.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful to Donna Tscherne, Thomas Pietschmann and Jin Zhong for discussions and for providing details of their experiments.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pcbi.1002307-Scarselli1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Scarselli</surname><given-names>E</given-names></name><name name-style="western"><surname>Ansuini</surname><given-names>H</given-names></name><name name-style="western"><surname>Cerino</surname><given-names>R</given-names></name><name name-style="western"><surname>Roccasecca</surname><given-names>RM</given-names></name><name name-style="western"><surname>Acali</surname><given-names>S</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.</article-title>             <source>EMBO J</source>             <volume>21</volume>             <fpage>5017</fpage>             <lpage>5025</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Pileri1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Pileri</surname><given-names>P</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Campagnoli</surname><given-names>S</given-names></name><name name-style="western"><surname>Galli</surname><given-names>G</given-names></name><name name-style="western"><surname>Falugi</surname><given-names>F</given-names></name><etal/></person-group>             <year>1998</year>             <article-title>Binding of hepatitis C virus to CD81.</article-title>             <source>Science</source>             <volume>282</volume>             <fpage>938</fpage>             <lpage>941</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Cormier1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Cormier</surname><given-names>EG</given-names></name><name name-style="western"><surname>Tsamis</surname><given-names>F</given-names></name><name name-style="western"><surname>Kajumo</surname><given-names>F</given-names></name><name name-style="western"><surname>Durso</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>JP</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>CD81 is an entry coreceptor for hepatitis C virus.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>101</volume>             <fpage>7270</fpage>             <lpage>7274</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Evans1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>MJ</given-names></name><name name-style="western"><surname>von Hahn</surname><given-names>T</given-names></name><name name-style="western"><surname>Tscherne</surname><given-names>DM</given-names></name><name name-style="western"><surname>Syder</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Panis</surname><given-names>M</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.</article-title>             <source>Nature</source>             <volume>446</volume>             <fpage>801</fpage>             <lpage>805</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Ploss1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ploss</surname><given-names>A</given-names></name><name name-style="western"><surname>Evans</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gaysinskaya</surname><given-names>VA</given-names></name><name name-style="western"><surname>Panis</surname><given-names>M</given-names></name><name name-style="western"><surname>You</surname><given-names>H</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Human occludin is a hepatitis C virus entry factor required for infection of mouse cells.</article-title>             <source>Nature</source>             <volume>457</volume>             <fpage>882</fpage>             <lpage>886</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Law1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Law</surname><given-names>M</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J</given-names></name><name name-style="western"><surname>Giang</surname><given-names>E</given-names></name><name name-style="western"><surname>Tarr</surname><given-names>AW</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.</article-title>             <source>Nat Med</source>             <volume>14</volume>             <fpage>25</fpage>             <lpage>27</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Dorner1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dorner</surname><given-names>M</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>JA</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>JB</given-names></name><name name-style="western"><surname>Barry</surname><given-names>WT</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>A genetically humanized mouse model for hepatitis C virus infection.</article-title>             <source>Nature</source>             <volume>474</volume>             <fpage>208</fpage>             <lpage>211</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-FafiKremer1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Fafi-Kremer</surname><given-names>S</given-names></name><name name-style="western"><surname>Fofana</surname><given-names>I</given-names></name><name name-style="western"><surname>Soulier</surname><given-names>E</given-names></name><name name-style="western"><surname>Carolla</surname><given-names>P</given-names></name><name name-style="western"><surname>Meuleman</surname><given-names>P</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.</article-title>             <source>J Exp Med</source>             <volume>207</volume>             <fpage>2019</fpage>             <lpage>2031</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Krieger1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Krieger</surname><given-names>SE</given-names></name><name name-style="western"><surname>Zeisel</surname><given-names>MB</given-names></name><name name-style="western"><surname>Davis</surname><given-names>C</given-names></name><name name-style="western"><surname>Thumann</surname><given-names>C</given-names></name><name name-style="western"><surname>Harris</surname><given-names>HJ</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.</article-title>             <source>Hepatology</source>             <volume>51</volume>             <fpage>1144</fpage>             <lpage>1157</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Harris1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Davis</surname><given-names>C</given-names></name><name name-style="western"><surname>Mullins</surname><given-names>JGL</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K</given-names></name><name name-style="western"><surname>Goodall</surname><given-names>M</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Claudin association with CD81 defines hepatitis C virus entry.</article-title>             <source>J Biol Chem</source>             <volume>285</volume>             <fpage>21092</fpage>             <lpage>21102</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Lemon1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lemon</surname><given-names>SM</given-names></name><name name-style="western"><surname>McKeating</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pietschmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Frick</surname><given-names>DN</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>JS</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Development of novel therapies for hepatitis C.</article-title>             <source>Antivir Res</source>             <volume>86</volume>             <fpage>79</fpage>             <lpage>92</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Zeisel1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zeisel</surname><given-names>MB</given-names></name><name name-style="western"><surname>Fofana</surname><given-names>I</given-names></name><name name-style="western"><surname>Fafi-Kremer</surname><given-names>S</given-names></name><name name-style="western"><surname>Baumert</surname><given-names>TF</given-names></name></person-group>             <year>2011</year>             <article-title>Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies.</article-title>             <source>J Hepatol</source>             <volume>54</volume>             <fpage>566</fpage>             <lpage>576</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Koutsoudakis1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Koutsoudakis</surname><given-names>G</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Kallis</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartenschlager</surname><given-names>R</given-names></name><name name-style="western"><surname>Pietschmann</surname><given-names>T</given-names></name></person-group>             <year>2007</year>             <article-title>The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.</article-title>             <source>J Virol</source>             <volume>81</volume>             <fpage>588</fpage>             <lpage>598</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Tscherne1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tscherne</surname><given-names>DM</given-names></name><name name-style="western"><surname>Evans</surname><given-names>MJ</given-names></name><name name-style="western"><surname>von Hahn</surname><given-names>T</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CT</given-names></name><name name-style="western"><surname>Stamataki</surname><given-names>Z</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Superinfection exclusion in cells infected with hepatitis C virus.</article-title>             <source>J Virol</source>             <volume>81</volume>             <fpage>3693</fpage>             <lpage>3703</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Zhong1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J</given-names></name><name name-style="western"><surname>Gastaminza</surname><given-names>P</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J</given-names></name><name name-style="western"><surname>Stamataki</surname><given-names>Z</given-names></name><name name-style="western"><surname>Isogawa</surname><given-names>M</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Persistent hepatitis C virus infection in vitro: coevolution of virus and host.</article-title>             <source>J Virol</source>             <volume>80</volume>             <fpage>11082</fpage>             <lpage>11093</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Kapadia1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kapadia</surname><given-names>SB</given-names></name><name name-style="western"><surname>Barth</surname><given-names>H</given-names></name><name name-style="western"><surname>Baumert</surname><given-names>T</given-names></name><name name-style="western"><surname>McKeating</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chisari</surname><given-names>FV</given-names></name></person-group>             <year>2007</year>             <article-title>Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I.</article-title>             <source>J Virol</source>             <volume>81</volume>             <fpage>374</fpage>             <lpage>383</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Brazzoli1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Brazzoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>S</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes.</article-title>             <source>J Virol</source>             <volume>82</volume>             <fpage>8316</fpage>             <lpage>8329</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Zhang1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>YY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>BH</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K</given-names></name><name name-style="western"><surname>Liang</surname><given-names>TJ</given-names></name></person-group>             <year>2010</year>             <article-title>Novel function of CD81 in controlling hepatitis C virus replication.</article-title>             <source>J Virol</source>             <volume>84</volume>             <fpage>3396</fpage>             <lpage>3407</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Magnus1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Magnus</surname><given-names>C</given-names></name><name name-style="western"><surname>Rusert</surname><given-names>P</given-names></name><name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name><name name-style="western"><surname>Trkola</surname><given-names>A</given-names></name><name name-style="western"><surname>Regoes</surname><given-names>RR</given-names></name></person-group>             <year>2009</year>             <article-title>Estimating the stoichiometry of human immunodeficiency virus entry.</article-title>             <source>J Virol</source>             <volume>83</volume>             <fpage>1523</fpage>             <lpage>1531</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Mulampaka1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Mulampaka</surname><given-names>SN</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name></person-group>             <year>2011</year>             <article-title>Estimating the threshold surface density of gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion.</article-title>             <source>PLoS One</source>             <volume>6</volume>             <fpage>e19941</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Neumann1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name><name name-style="western"><surname>Lam</surname><given-names>NP</given-names></name><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name><name name-style="western"><surname>Gretch</surname><given-names>DR</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>TE</given-names></name><etal/></person-group>             <year>1998</year>             <article-title>Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.</article-title>             <source>Science</source>             <volume>282</volume>             <fpage>103</fpage>             <lpage>107</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Zeuzem1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Fricke</surname><given-names>J</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name><etal/></person-group>             <year>2001</year>             <article-title>Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha-2a.</article-title>             <source>Gastroenterology</source>             <volume>120</volume>             <fpage>1438</fpage>             <lpage>1447</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Herrmann1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Herrmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Marinos</surname><given-names>G</given-names></name><name name-style="western"><surname>Modi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name></person-group>             <year>2003</year>             <article-title>Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.</article-title>             <source>Hepatology</source>             <volume>37</volume>             <fpage>1351</fpage>             <lpage>1358</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Dixit1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name><name name-style="western"><surname>Layden-Almer</surname><given-names>JE</given-names></name><name name-style="western"><surname>Layden</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name></person-group>             <year>2004</year>             <article-title>Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.</article-title>             <source>Nature</source>             <volume>432</volume>             <fpage>922</fpage>             <lpage>924</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Dahari1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name></person-group>             <year>2007</year>             <article-title>Triphasic decline of hepatitis C virus RNA during antiviral therapy.</article-title>             <source>Hepatology</source>             <volume>46</volume>             <fpage>16</fpage>             <lpage>21</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Colombatto1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Colombatto</surname><given-names>P</given-names></name><name name-style="western"><surname>Ciccorossi</surname><given-names>P</given-names></name><name name-style="western"><surname>Maina</surname><given-names>AM</given-names></name><name name-style="western"><surname>Civitano</surname><given-names>L</given-names></name><name name-style="western"><surname>Oliveri</surname><given-names>F</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Early and accurate prediction of peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells.</article-title>             <source>Clin Pharmacol Ther</source>             <volume>84</volume>             <fpage>212</fpage>             <lpage>215</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Rong1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>L</given-names></name><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name></person-group>             <year>2010</year>             <article-title>Rapid emergence of protease inhibitor resistance in hepatitis C virus.</article-title>             <source>Sci Transl Med</source>             <volume>2</volume>             <fpage>30ra32</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Rong2">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>L</given-names></name><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name></person-group>             <year>2010</year>             <article-title>Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.</article-title>             <source>Crit Rev Immunol</source>             <volume>30</volume>             <fpage>131</fpage>             <lpage>148</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Adiwijaya1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Adiwijaya</surname><given-names>BS</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Hare</surname><given-names>B</given-names></name><name name-style="western"><surname>Kieffer</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.</article-title>             <source>PLoS Comput Biol</source>             <volume>6</volume>             <fpage>e1000745</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Guedj1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Guedj</surname><given-names>J</given-names></name><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name></person-group>             <year>2011</year>             <article-title>Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration.</article-title>             <source>Hepatology</source>             <volume>53</volume>             <fpage>1801</fpage>             <lpage>1808</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Hsu1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>CS</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HC</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>TC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CH</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>108</volume>             <fpage>3719</fpage>             <lpage>3724</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Walters1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Walters</surname><given-names>KA</given-names></name><name name-style="western"><surname>Syder</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lederer</surname><given-names>SL</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>DL</given-names></name><name name-style="western"><surname>Paeper</surname><given-names>B</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes.</article-title>             <source>PLoS Pathog</source>             <volume>5</volume>             <fpage>e1000269</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-DebRoy1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>DebRoy</surname><given-names>S</given-names></name><name name-style="western"><surname>Kribs-Zaleta</surname><given-names>C</given-names></name><name name-style="western"><surname>Mubayi</surname><given-names>A</given-names></name><name name-style="western"><surname>Cardona-Melendez</surname><given-names>GM</given-names></name><name name-style="western"><surname>Medina-Rios</surname><given-names>L</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Evaluating treatment of hepatitis C for hemolytic anemia management.</article-title>             <source>Mathematical Biosciences</source>             <volume>225</volume>             <fpage>141</fpage>             <lpage>155</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Krishnan1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Krishnan</surname><given-names>SM</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name></person-group>             <year>2011</year>             <article-title>Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.</article-title>             <source>PLoS Comput Biol</source>             <volume>7</volume>             <fpage>e1001072</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Wakita1">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wakita</surname><given-names>T</given-names></name><name name-style="western"><surname>Pietschmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Date</surname><given-names>T</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>M</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.</article-title>             <source>Nat Med</source>             <volume>11</volume>             <fpage>791</fpage>             <lpage>796</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Zhong2">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J</given-names></name><name name-style="western"><surname>Gastaminza</surname><given-names>P</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G</given-names></name><name name-style="western"><surname>Kapadia</surname><given-names>S</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Robust hepatitis C virus infection in vitro.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>102</volume>             <fpage>9294</fpage>             <lpage>9299</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Lindenbach1">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lindenbach</surname><given-names>BD</given-names></name><name name-style="western"><surname>Evans</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Syder</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wölk</surname><given-names>B</given-names></name><name name-style="western"><surname>Tellinghuisen</surname><given-names>TL</given-names></name><etal/></person-group>             <year>2005</year>             <article-title>Complete replication of hepatitis C virus in cell culture.</article-title>             <source>Science</source>             <volume>309</volume>             <fpage>623</fpage>             <lpage>626</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Ploss2">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ploss</surname><given-names>A</given-names></name><name name-style="western"><surname>Khetani</surname><given-names>SR</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CT</given-names></name><name name-style="western"><surname>Syder</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Trehan</surname><given-names>K</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>107</volume>             <fpage>3141</fpage>             <lpage>3145</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Guedj2">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Guedj</surname><given-names>J</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name></person-group>             <year>2010</year>             <article-title>Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.</article-title>             <source>J Theor Biol</source>             <volume>267</volume>             <fpage>330</fpage>             <lpage>340</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Dahari2">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name><name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name></person-group>             <year>2007</year>             <article-title>Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells.</article-title>             <source>J Virol</source>             <volume>81</volume>             <fpage>750</fpage>             <lpage>760</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Dahari3">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name><name name-style="western"><surname>Sainz</surname><given-names>B</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name><name name-style="western"><surname>Uprichard</surname><given-names>SL</given-names></name></person-group>             <year>2009</year>             <article-title>Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon.</article-title>             <source>J Virol</source>             <volume>83</volume>             <fpage>6383</fpage>             <lpage>6390</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Hofmann1">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hofmann</surname><given-names>WP</given-names></name><name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name></person-group>             <year>2011</year>             <article-title>A new standard of care for the treatment of chronic HCV infection.</article-title>             <source>Nat Rev Gastroenterol Hepatol</source>             <volume>8</volume>             <fpage>257</fpage>             <lpage>264</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Nakajima1">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Nakajima</surname><given-names>H</given-names></name><name name-style="western"><surname>Cocquerel</surname><given-names>L</given-names></name><name name-style="western"><surname>Kiyokawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>J</given-names></name><name name-style="western"><surname>Levy</surname><given-names>S</given-names></name></person-group>             <year>2005</year>             <article-title>Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop.</article-title>             <source>Biochem Biophys Res Commun</source>             <volume>328</volume>             <fpage>1091</fpage>             <lpage>1100</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Baksh1">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Baksh</surname><given-names>MM</given-names></name><name name-style="western"><surname>Kussrow</surname><given-names>AK</given-names></name><name name-style="western"><surname>Mileni</surname><given-names>M</given-names></name><name name-style="western"><surname>Finn</surname><given-names>MG</given-names></name><name name-style="western"><surname>Bornhop</surname><given-names>DJ</given-names></name></person-group>             <year>2011</year>             <article-title>Label-free quantification of membrane-ligand interactions using backscattering interferometry.</article-title>             <source>Nat Biotechnol</source>             <volume>29</volume>             <fpage>357</fpage>             <lpage>360</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Flint1">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Flint</surname><given-names>M</given-names></name><name name-style="western"><surname>Von Hahn</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Farquhar</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CT</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Diverse CD81 proteins support hepatitis C virus infection.</article-title>             <source>J Virol</source>             <volume>80</volume>             <fpage>11331</fpage>             <lpage>11342</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-RochaPerugini1">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Rocha-Perugini</surname><given-names>V</given-names></name><name name-style="western"><surname>Lavie</surname><given-names>M</given-names></name><name name-style="western"><surname>Delgrange</surname><given-names>D</given-names></name><name name-style="western"><surname>Canton</surname><given-names>J</given-names></name><name name-style="western"><surname>Pillez</surname><given-names>A</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>The association of CD81 with tetraspanin-enriched microdomains is not essential for hepatitis C virus entry.</article-title>             <source>BMC Microbiol</source>             <volume>9</volume>             <fpage>111</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Brimacombe1">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Brimacombe</surname><given-names>CL</given-names></name><name name-style="western"><surname>Grove</surname><given-names>J</given-names></name><name name-style="western"><surname>Meredith</surname><given-names>LW</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K</given-names></name><name name-style="western"><surname>Syder</surname><given-names>AJ</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Neutralizing antibody resistant hepatitis C virus cell-to-cell transmission.</article-title>             <source>J Virol</source>             <volume>85</volume>             <fpage>596</fpage>             <lpage>605</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Kannan1">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kannan</surname><given-names>RP</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>LL</given-names></name><name name-style="western"><surname>Evers</surname><given-names>LE</given-names></name><name name-style="western"><surname>Lemon</surname><given-names>SM</given-names></name><name name-style="western"><surname>McGivern</surname><given-names>DR</given-names></name></person-group>             <year>2011</year>             <article-title>Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis.</article-title>             <source>J Virol</source>             <volume>85</volume>             <fpage>7989</fpage>             <lpage>8001</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Beauchemin1">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Beauchemin</surname><given-names>CAA</given-names></name><name name-style="western"><surname>McSharry</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Went</surname><given-names>GT</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Modeling amantadine treatment of influenza A virus in vitro.</article-title>             <source>J Theor Biol</source>             <volume>254</volume>             <fpage>439</fpage>             <lpage>451</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Sabahi1">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sabahi</surname><given-names>A</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>KA</given-names></name><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>P</given-names></name><name name-style="western"><surname>Lamora</surname><given-names>JM</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>The rate of hepatitis C virus infection initiation in vitro is directly related to particle density.</article-title>             <source>Virology</source>             <volume>407</volume>             <fpage>110</fpage>             <lpage>119</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Bell1">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>GI</given-names></name></person-group>             <year>1978</year>             <article-title>Models for the specific adhesion of cells to cells.</article-title>             <source>Science</source>             <volume>200</volume>             <fpage>618</fpage>             <lpage>627</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Wu1">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zarnitsyna</surname><given-names>VI</given-names></name><name name-style="western"><surname>Tolentino</surname><given-names>TP</given-names></name><name name-style="western"><surname>Dustin</surname><given-names>ML</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>A coupled diffusion-kinetics model for analysis of contact-area FRAP experiment.</article-title>             <source>Biophys J</source>             <volume>95</volume>             <fpage>910</fpage>             <lpage>919</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Yu1">
        <label>53</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Atanasov</surname><given-names>I</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles.</article-title>             <source>Virology</source>             <volume>367</volume>             <fpage>126</fpage>             <lpage>134</lpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Sougrat1">
        <label>54</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sougrat</surname><given-names>R</given-names></name><name name-style="western"><surname>Bartesaghi</surname><given-names>A</given-names></name><name name-style="western"><surname>Lifson</surname><given-names>JD</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>AE</given-names></name><name name-style="western"><surname>Bess</surname><given-names>JW</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry.</article-title>             <source>PLoS Pathog</source>             <volume>3</volume>             <fpage>e63</fpage>          </element-citation>
      </ref>
      <ref id="pcbi.1002307-Zhang2">
        <label>55</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Randall</surname><given-names>G</given-names></name><name name-style="western"><surname>Higginbottom</surname><given-names>A</given-names></name><name name-style="western"><surname>Monk</surname><given-names>P</given-names></name><name name-style="western"><surname>Rice</surname><given-names>CM</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.</article-title>             <source>J Virol</source>             <volume>78</volume>             <fpage>1448</fpage>             <lpage>1455</lpage>          </element-citation>
      </ref>
    </ref-list>
    
  </back>
</article>